Cochat and Rumsby [1] published that the life-birth incidence of PH1 in a European cohort is approximately 1 in 120,000 and therefore, it is likely that in 2019 worldwide 1168 newborns had PH1 mutations and will sooner or later present with clinically observable consequences of a PH1 mutation. This evidence concerns the gene AGXT and primary hyperoxaluria type 1.